middle.news
Imricor Builds Regulatory and Clinical Momentum with US$7.8M Q1 Outflow
9:00am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Imricor Builds Regulatory and Clinical Momentum with US$7.8M Q1 Outflow
9:00am on Tuesday 28th of April, 2026 AEST
Key Points
FDA clears NorthStar and Vision-MR catheters in January
Expanded VISABL-AFL trial sites in US and Europe
Submitted Advantage-MR system for FDA 510(k) clearance
Q1 operating cash outflow rises to US$7.8 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imricor Medical Systems (ASX:IMR)
OPEN ARTICLE